Showing results (271-280 of 520) with videos related to

Sort By:
Pageof 52
Vaccine|June 14, 2023
Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in older US adultsAngela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, et al.
Journal of the National Medical Association|June 8, 2019
Racial Disparities in Adult Pneumococcal Vaccination Indications and Pneumococcal Hospitalizations in the U.SMary Patricia Nowalk, Angela R Wateska, Chyongchiou Jeng Lin, et al.
American Journal of Preventive Medicine|June 21, 2021
Higher-Valency Pneumococcal Conjugate Vaccines: An Exploratory Cost-Effectiveness Analysis in U.S. SeniorsKenneth J Smith, Angela R Wateska, Mary Patricia Nowalk, et al.
Journal of Contaminant Hydrology|March 14, 2018
DFN-M field characterization of sandstone for a process-based site conceptual model and numerical simulations of TCE transport with degradationAmanda A Pierce, Steven W Chapman, Laura K Zimmerman, et al.
Journal of Pediatric Health Care : Official Publication of National Association of Pediatric Nurse Associates & Practitioners|August 10, 2015
Reducing Racial Disparities in Influenza Vaccination Among Children With AsthmaChyongchiou Jeng Lin, Mary Patricia Nowalk, Richard K Zimmerman, et al.
American Journal of Preventive Medicine|February 13, 2016
Cost Effectiveness of Influenza Vaccine Choices in Children Aged 2-8 Years in the U.SKenneth J Smith, Jonathan M Raviotta, Jay V DePasse, et al.
American Journal of Preventive Medicine|November 30, 2024
Cost-Effectiveness and Public Health Impact of 24-Valent Pneumococcal Conjugate Vaccine Compared With the Recommended Pneumococcal Vaccines in Older AdultsKenneth J Smith, Angela R Wateska, Mary Patricia Nowalk, et al.
Journal of the American Geriatrics Society|February 23, 2020
Cost-Effectiveness of Pneumococcal Vaccination Policies and Uptake Programs in US Older PopulationsAngela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, et al.
American Journal of Preventive Medicine|February 1, 2020
Pneumococcal Vaccination in Adults Aged ≥65 Years: Cost-Effectiveness and Health Impact in U.S. PopulationsAngela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, et al.
Vaccine|June 25, 2021
Should older adult pneumococcal vaccination recommendations change due to decreased vaccination in children during the pandemic? A cost-effectiveness analysisKenneth J Smith, Angela R Wateska, Mary Patricia Nowalk, et al.
Pageof 52